Besilesomab

Besilesomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CEA-related antigen
Clinical data
Trade names	Scintimun
ATC code	none;
Identifiers
CAS Number	537694-98-7 ;
ChemSpider	none;
	(what is this?) (verify)

Besilesomab (trade name Scintimun) is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m. It is used to detect inflammatory lesions and metastases. It binds to an immunoglobulin, IgG1 isotype. SCINTIMUN has been used since 1992 mainly in Hungary, Czech Republic, and Switzerland on the basis of local marketing authorizations, and in Germany (on the basis of individual prescription). Between 1992 and 2009, an estimated 90,000 patients has been studied. In 2009, the EMEA has approved SCINTIMUN for marketing in all European countries.^[1]^[2]

References

^ WHO Drug Information
^ Positive opinion of the CHMP for SCINTIMUN (Besilesomab) Archived December 25, 2009, at the Wayback Machine

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] WHO Drug Information

[2] Positive opinion of the CHMP for SCINTIMUN (Besilesomab) Archived December 25, 2009, at the Wayback Machine

[1]

[2]